Vision and strategy

Drug discovery and development is a highly complex business. We take a proactive, risk-based approach to the process, founded on diversification and constant practical and commercial evaluation of our candidates.

As well as maintaining a tight, commercially-driven pipeline, Vernalis aims to leverage the key strengths of our organisation to maximum advantage. These strengths include:

• Dynamic and experienced leadership

  Having already headed up successful drug development companies, Chief Executive Officer Ian Garland and Chief Financial Officer David Mackney are the perfect team to help Vernalis realise its potential

• Strong cash position

  Supportive shareholder take-up of our recent fundraisings together with royalty income from our marketed product, frovatriptan, provides cash through to the end of 2013

• Broad and maturing pipeline

  Drug candidates in development span a range of conditions and fields, and are in varying stages of advancement

• Highly productive quality research

  Including world-leading capabilities in fragment-based and structure-based drug discovery

• Partner validation

  Clear endorsement from many leading global pharmaceutical companies, including Endo, GSK, Lundbeck, Menarini, Novartis and Servier

Latest News